Clinical Trials Logo

Antiphospholipid Syndrome clinical trials

View clinical trials related to Antiphospholipid Syndrome.

Filter by:

NCT ID: NCT00180817 Completed - Clinical trials for Antiphospholipid Syndrome

Longitudinal Study of the Clinical and Haematological Cause of Women With Antiphospholipid Antibodies.

Start date: September 1998
Phase:
Study type: Observational

This study is being done to see if there are any long term health related issues in women with APA and recurrent miscarriages.

NCT ID: NCT00180778 Withdrawn - Clinical trials for Antiphospholipid Syndrome

Steroids and Antiphospholipid Syndrome- Related Pregnancy Loss

Start date: October 2005
Phase: Phase 1/Phase 2
Study type: Interventional

Does the addition of steroids during the first trimester to the standard aspirin + heparin treatment reduce the miscarriage rates in women with antiphospholipid antibodies and recurrent first trimester miscarriage in those who had an unsuccessful pregnancy with aspirin + heparin?

NCT ID: NCT00076713 Completed - Clinical trials for Antiphospholipid Syndrome

Antiphospholipid Syndrome Collaborative Registry (APSCORE)

APSCORE
Start date: April 2000
Phase: N/A
Study type: Observational

Antiphospholipid Syndrome (APS) is an autoimmune disorder in which the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodies against them. Patients with these antibodies may experience miscarriages and blood clotting disorders, including heart attacks and strokes. APS may occur in people with systemic lupus erythematosus and other autoimmune diseases, or in otherwise healthy individuals. The Antiphospholipid Syndrome Collaborative Registry (APSCORE) is a national registry and tissue repository for patients with APS. This registry will collect clinical information and blood samples from people with APS.

NCT ID: NCT00010400 Completed - Clinical trials for Systemic Lupus Erythematosus

Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome

Start date: April 1997
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Determine the induction of durable remission in patients with life-threatening systemic lupus erythematosus or antiphospholipid antibody syndrome treated with cyclophosphamide. II. Determine the toxicity of this drug in these patients.